CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2018--
Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates
at two upcoming investor conferences in March:
2018 Cowen and Company 38th Annual Health Care Conference on Monday,
March 12, 2018 at 11:20 a.m. ET at The Boston Marriott Copley Place in
Barclays Global Healthcare Conference on Thursday, March 15, 2018 at
10:15 a.m. ET at the Loews Miami Beach Hotel in Miami.
A live webcast of Ironwood’s presentations will be accessible through
the Investors section of the company’s website at www.ironwoodpharma.com.
To access the webcasts, please log on to the Ironwood website
approximately 15 minutes prior to the start time to ensure adequate time
for any software downloads that may be required. A replay of the
webcasts will be available on Ironwood’s website for 14 days following
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS‐C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
for the treatment of hyperuricemia associated with gout in patients who
have not achieved target serum uric acid (sUA) levels with a medically
appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We
are also advancing a pipeline of innovative product candidates in areas
of significant unmet need, including uncontrolled gastroesophageal
reflux disease, diabetic nephropathy, heart failure with preserved
ejection fraction, achalasia and sickle cell disease. Ironwood was
founded in 1998 and is headquartered in Cambridge, Mass. For more
information, please visit www.ironwoodpharma.com
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305006122/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
President, Investor Relations and Corporate Communications